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Age-related hearing impairment (ARHI) is the most prevalent sensory impairment in the elderly. ARHI is a
complex disease caused by an interaction between environmental and genetic factors. The contribution of
various environmental factors has been relatively extensively studied. In contrast, investigations to identify
the genetic risk factors have only recently been initiated. In this paper we describe the results of an associ-
ation study performed on 2418 ARHI samples derived from nine centers from seven European countries. In 70
candidate genes, a total of 768 tag single nucleotide polymorphisms (SNPs) were selected based on HAPMAP
data. These genes were chosen among the monogenic hearing loss genes identified in mice and men in
addition to several strong functional candidates. After genotyping and data polishing, statistical analysis
of all samples combined resulted in a P-value that survived correction for multiple testing for one SNP in
the GRHL2 gene. Other SNPs in this gene were also associated, albeit to a lesser degree. Subsequently,
an analysis of the most significant GRHL2 SNP was performed separately for each center. The direction of
the association was identical in all nine centers. Two centers showed significant associations and a third
center showed a trend towards significance. Subsequent fine mapping of this locus demonstrated that the
majority of the associated SNPs reside in intron 1. We hypothesize that the causative variant may change
the expression levels of a GRHL2 isoform.
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INTRODUCTION
Age-related hearing impairment (ARHI), or presbyacusis, is
the most common sensory impairment seen in the elderly.
Approximately 60% of people aged between 71 and 80
suffer from an impairment of 25 dB or more (1). As the
overall population in developed countries is aging, the
number of ARHI subjects is expected to increase steadily
during the coming years.
ARHI is a complex disorder with both environmental and
genetic factors contributing to the sensory deficit as indicated
by several heritability studies (2–5). Heritability estimates
ranged between 0.25 and 0.75 depending on the study
design (family versus twin study), the frequency range (low
versus high frequencies), the age range (below 65 or above),
the pathological type (strial versus sensory ARHI) and the
method of measuring hearing (self-reported hearing impair-
ment versus pure tone or speech audiometric measurements).
The impact of several environmental risk factors has been
investigated extensively. These include noise exposure (6–
8), ototoxic medication (9,10), and exposure to chemicals
(11,12). Certain medical conditions such as diabetes (13), car-
diovascular disease (14) and renal failure (15) may also have
an impact on ARHI. The effects of nutritional status (16–
18), tobacco smoking (9,19,20), alcohol (ab)use (9,19,21)
and bone mass density (22–24) remain controversial.
Less is known concerning the nature of the genetic factors
involved in the development of ARHI as these have only
recently attracted the attention of scientists. So far, two
genome wide linkage studies have been performed, resulting
in the localization of seven different susceptibility regions
for ARHI (25,26). In addition, a number of association
studies on candidate susceptibility genes have been performed.
Three of these failed to detect significant associations
with ARHI (27–29). Other studies succeeded in identifying
genes that are associated with ARHI. A significant association
was found between ARHI and a polymorphism in N-acetyl-
transferase (NAT2), an enzyme involved in the metabolism
and detoxification of cytotoxic and carcinogenic compounds
(30). We recently replicated this finding in an independent
population (31). In the latter study we also found evidence
for an association of the GSTM1 (glutathione s-transferase,
mu-1) and GSTT1 (glutathione s-transferase, theta-1) deletion
polymorphisms and ARHI in the Finnish population (31). In
addition, we previously demonstrated that ARHI was associ-
ated with several SNPs in a 13 kb region in KCNQ4 (potass-
ium channel, voltage-gated, kqt-like subfamily, member 4)
(32). Finally, an apparent protective effect of apolipoprotein
E (APOE) allele 14 was recently suggested (33).
Although whole genome association studies are feasible
nowadays, they remain very expensive. Therefore, to identify
susceptibility genes involved in complex disorders, a candi-
date gene approach is often pursued. In the case of ARHI, a
whole range of candidate genes can be proposed as the percep-
tion of sound requires complex pathways and age-related
changes in any component of these pathways may contribute
to ARHI. Genes causing monogenic forms of hearing loss
are excellent candidate susceptibility genes for ARHI. Other
genes can be considered candidates on the basis of a known
or presumed function in the inner ear. Here we present the
results of an association study on 70 candidate genes, which
were chosen among the monogenic hearing loss genes identi-
fied in mice and men in addition to several strong functional
candidates. In this study we used 2418 ARHI samples
derived from nine centers from seven European countries.
RESULTS
Results of the genotyping project and data polishing
The 34% extremes from 3530 samples were selected for both
genders and for each center separately (Table 1 and Sup-
plementary Material, Fig. S1). Two thousand four hundred
and fifty four selected samples (including 36 duplicate
samples) were genotyped for 768 SNPs selected from 70
candidate genes (Tables 2, 3 and Supplementary Material,
Table S1). An overview of the success rates of the genotyping
project is given in Table 4. The overall success rate was
92.93%. Moreover, the Illumina genotyping method gave
highly reproducible results (Table 4). Checking 3432 of the
Illumina genotypes with an alternative genotyping method in
our laboratory setting, resulted in an accuracy of 99.94%.
The subsequent removal of genetic outliers based on CHECK-
HET and GRR (graphical representation of relationship errors)
resulted in a final number of 2318 samples for which results
were suitable for statistical analysis (Table 1).
Association analysis
Although the minor allele frequency (MAF) cut-off value was
set at 0.05 during SNP selection based on HAPMAP data, 19
SNPs were below that cut-off value when genotyped on our
sample sets. Hence, despite the fact that Illumina had success-
fully genotyped 722 SNPs, only 703 were taken forward for
statistical analysis. As a first step, the homogeneity of the gen-
otyping results across the different centers was tested using
logistic regression. If this test was not significant, the
samples of all centers were combined and a reduced logistic
regression model was fitted to analyze the effect of the geno-
types on the ARHI phenotype. Table 5 lists the 20 top-ranked
SNPs resulting from the combined analysis. When we applied
a Bonferroni correction for multiple testing (0.05/
703 ¼ 7.11025), none of the P-values remained significant.
However, the top-ranked SNP, rs10955255 in GRHL2 (grainy-
head like 2), almost reached this Bonferroni-corrected signifi-
cance level (8.4  1025). Since not all 703 tests were
independent because of linkage disequilibrium (LD) between
SNPs, a Bonferroni correction for multiple testing can be con-
sidered too conservative. Moreover, false discovery rate
(FDR) calculations resulted in a Q-value of 0.054, which indi-
cates that the probability of this association being spurious was
only 5%. Interestingly, all the three top-ranked SNPs resided
in GRHL2 in a region of approximately 16 kb. These three
GRHL2 SNPs were in LD (data not shown). The FDR
Q-value for the third-ranked SNP (rs1981361) was 0.081, indi-
cating that among the three top-ranked SNPs, only 8% were
expected to be false discoveries. Taking everything into
account, we concluded that the GRHL2 result represents a
genuine association.
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Ten from the 20 top-ranked SNPs were localized in
PCDH15 (protocadherin 15). Because the Bonferroni-
corrected significance limit was never reached for the com-
bined analysis of the 10 PCDH15 top-ranked SNPs
(a minimum P-value of 0.0015 was obtained; Table 5), and
because FDR Q-values of 0.249 and higher were calculated,
this lead was not pursued.
Next, the directions of the associations were analyzed for all
SNPs in all centers separately. For only three out of 703 SNPs,
all odds ratios (ORs) pointed in the same direction: GRHL2
SNPs rs10955255 and rs2127034 (ranked 1 and 2, respect-
ively) and PCDH15 SNP rs7087057 (ranked 11). This fact
provided further evidence for the validity of the association
between GRHL2 SNPs rs10955255 and rs2127034 and ARHI.
For GRHL2 SNP rs10955255, significant associations were
observed for the centers of Oulu and Padova (P-values of
0.0020 and 0.0036, respectively; Table 6), while for Tu¨bingen
a trend towards significance was observed (P-value ¼ 0.082;
Table 6). ORs ranged between 1.02 and 1.76. For all popu-
lations except Ghent, the GG genotype was more often
present in subjects with worse hearing than in better hearing
subjects. The AA genotype was protective as it was more fre-
quent in better hearing subjects than in worse hearing subjects
(Fig. 1). For GRHL2 SNP rs2127034, the Oulu subsample was
significantly associated with ARHI (P-value ¼ 0.0009;
Table 6) and ORs ranged between 0.58 and 0.92. Sub-
sequently, the association between ARHI and variations in
GRHL2 was further elaborated.
GRHL2 fine mapping
For fine mapping purposes 44 additional tag-SNPs and a non-
synonymous SNP located in exon 2 (rs3735709) were geno-
typed. A sample success rate of 95.3% (114 samples missing
from 2418), a SNP success rate of 91.1% (41 SNPs from
45) and an overall success rate of 86.8% were obtained.
The results of the statistical analysis of the 26 original and
the 41 fine-mapping GRHL2 SNPs on all samples combined
are shown in Table 7 and in Supplementary Material,
Table S2. Besides the three top SNPs from the first analysis
(rs10955255, rs2127034 and rs1981361), one additional SNP
(rs13263539) was highly significantly associated with ARHI
with a P-value of 0.0002. In addition, six SNPs were associ-
ated with P-values ranging between 0.01 and 0.04. The non-
synonymous SNP in exon 2 (rs3735709), which was located
in close proximity of SNPs rs10955255 and rs2127034 and
as such a putative causative SNP, was not significantly associ-
ated with ARHI.
Subsequently, we investigated the LD patterns within
GRHL2 with Haploview. In addition, we looked for putative
regulatory regions with Genomatix (Fig. 2). The four highly
significant SNPs and two of the less significant SNPs all
resided in one 18 kb LD-block located in the second half of
intron 1. One of the predicted promoter regions was located
within this LD-block (Fig. 2), and it also contained a few
regions that were conserved between man and mouse (Sup-
plementary Material, Fig. S2). The remaining four less signifi-
cant SNPs were present in the last part of the gene. SNPs
rs812890 and rs12114698 reside in the associated 18 kb
Table 1. Overview of sample numbers
Country Center Number of
samples collected
Number of women
selected
Number of men
selected
Total selected Total removeda Available for
analyses
Belgium Antwerp 769 276 248 524 19 505
United Kingdom Cardiff 368 112 140 252 23 229
Denmark Copenhagen 404 138 140 278 9 269
Belgium Ghent 198 76 60 136 5 131
The Netherlands Nijmegen 276 88 100 188 4 184
Finland Oulu 505 196 150 346 11 335
Italy Padova 359 130 116 246 13 233
Finland Tampere 256 106 70 176 5 171
Germany Tu¨bingen 395 134 138 272 11 261
Total 3530 1256 1162 2418 100 2318
aThis number includes samples that failed genotyping, those with a gender mismatch and genetic outliers detected by CHECKHET or GRR.
Table 2. Classification of candidate genes
Category Number of genes
Non-syndromica 36
Functional 14
Mouse 8
Oxidative stress 5
Syndromic 3
Expression 2
Y-chromosome 1
Stratification 1
Total 70
aGenes leading to both syndromic and non-syndromic hearing loss were
classified as non-syndromic genes.
Table 3. Classification of selected SNPs
Category Number of SNPs Percentage (%)
Intronic 623 81.1
Exon/non-synonymous 61 7.9
Exon/synonymous 13 1.7
UTR 25 3.3
Locus 46 6.0
Total 768 100.0
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LD-block, but were not significantly associated. This is most
likely due to their low MAF of 0.018 and 0.014, respectively.
To test whether all significant SNPs were attributable to the
same association signal, we performed an allelic heterogeneity
test. With this analysis we investigated whether LD with the
most significant SNP (rs10955255) accounted for all other
associated SNPs. The results showed that all associated SNPs
residing in the 18 kb haplotype block represent a single associ-
ation signal and, hence, the same underlying causative mutation
(Supplementary Material, Table S3). From the associated SNPs
in the distal part of the gene, all but one were attributable to that
same association signal. Only SNP rs7827945 seems to be inde-
pendent. This latter association was not very significant and
may be coincidental.
Haploview enabled us to determine the risk haplotype in the
18 kb LD-block (Table 8). The most frequent haplotype,
GCAATAGAG, is also the risk conferring haplotype with a
P-value of 0.0003.
DISCUSSION
Our ARHI candidate gene study, consisting of the analysis of
768 SNPs selected in 70 genes, has identified GRHL2, alias
BOM (brother of mammalian grainyhead) or TFCP2L3
Table 4. Summary of the results of the genotyping project
Parameter Number of successful genotypes Number of possible genotypes Success rate (%)
Sample success ratea 2429 2454 98.98
Locus success rateb 722 768 94.01
Genotypes (call rate)c 1745275f 1747547f 99.87
Reproducibilityd 36 36 100
Overall success ratee 1745275f 1878019f 92.93
aNumber of samples out of the total attempted for which genotypes were delivered.
bNumber of assays designed for the multiplex analysis that were successful in producing genotypes at the desired loci.
cNumber of genotypes delivered for all successful samples at all successful loci.
dReproducibility of the replicate sample pairs.
eNumber of genotypes delivered for all samples at all loci.
fExcludes Y-genotype calls on female samples.
Table 5. Top 20 of associated SNPs in all samples combined
Rank Gene SNP Chr Coordinate MAF Homogeneity P-value OR
1 GRHL2 rs10955255 8 102605581 0.400 0.2948 8.381025 1.27
2 GRHL2 rs2127034 8 102611574 0.467 0.5885 0.000160 0.80
3 GRHL2 rs1981361 8 102621953 0.404 0.0728 0.000529 0.81
4 EYA4 rs212765 6 133831944 0.460 0.3255 0.000565 1.23
5 ITGA8 rs2236579 10 15802120 0.168 0.8402 0.000606 0.76
6 PCDH15 rs7081730 10 55703027 0.283 0.6018 0.001507 1.23
7 PCDH15 rs11004270 10 55817364 0.255 0.6827 0.001698 0.80
8 KCNQ1 rs12277647 11 2420601 0.301 0.7407 0.001710 1.22
9 KCNMA1 rs697173 10 78883639 0.378 0.7568 0.001967 0.83
10 PCDH15 rs996320 10 55671084 0.279 0.7127 0.001983 1.23
11 PCDH15 rs7087057 10 55682161 0.26 0.8476 0.002025 0.81
12 PCDH15 rs978842 10 55735045 0.269 0.4529 0.002579 0.81
13 PCDH15 rs7476518 10 55661120 0.278 0.7054 0.004174 1.21
14 ITGA8 rs1417664 10 15778660 0.292 0.2526 0.005117 1.20
15 PCDH15 rs1900443 10 55278131 0.143 0.0704 0.006731 1.25
16 PCDH15 rs10509013 10 55957107 0.229 0.1335 0.007234 1.21
17 CAT rs2300181 11 34433115 0.230 0.8105 0.008213 1.21
18 PCDH15 rs11004142 10 55642037 0.343 0.7360 0.008259 0.85
19 PCDH15 rs12258253 10 55298564 0.142 0.6267 0.014513 0.81
20 EYA4 rs9321402 6 133836204 0.299 0.4520 0.016562 0.86
Chr, chromosome; MAF, minor allele frequency; OR, odds ratio.
Table 6. Association analysis of the two most significant GRHL2 SNPs in all
centers separately
Center rs10955255 rs2127034
OR P-value OR P-value
Antwerp 1.05 0.7199 0.92 0.4922
Cardiff 1.12 0.5706 0.88 0.4998
Copenhagen 1.28 0.1995 0.90 0.5481
Ghent 1.02 0.9421 0.82 0.3985
Nijmegen 1.17 0.4667 0.78 0.2352
Oulu 1.67 0.0020 0.58 0.0009
Padova 1.76 0.0036 0.73 0.0794
Tampere 1.22 0.4153 0.91 0.6881
Tu¨bingen 1.36 0.0821 0.76 0.1056
Significant P-values have been indicated in bold.
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(transcription factor cellular promoter 2-like 3), as an ARHI
susceptibility gene. This conclusion was based on several find-
ings: four SNPs residing in one 18 kb LD-block were highly
significantly associated with ARHI in a combined analysis
of all samples, the most significant SNP was replicated in
two out of nine independent sample sets, and the ORs of all
nine sample sets pointed in the same direction. In addition,
the GG-genotype was more prominent in worse hearing sub-
jects than in better hearing subjects for all but one center
(Ghent). Up to now, we have not been able to find a reasonable
explanation for the discrepant picture obtained in the samples
from Ghent. These samples have been collected using exactly
the same criteria as for the other samples. In addition, Ghent is
very close to Antwerp and Nijmegen geographically. The
Ghent subsample contained the smallest number of samples,
and was consequently the least powerful subset. As such, a
plausible explanation might be that these results deviate
from the others simply by chance.
A preliminary analysis of audiogram shapes has indicated
that the Ghent subsample has a higher proportion of flat-
shaped audiograms, while in most of the other subsamples
the high-frequency steeply sloping audiogram shape is the
most prominent (unpublished data). Inherent on the Z-score
method, a subject with a flat audiogram is more likely to be
included among the controls. Interestingly, Ghent had a rela-
tively higher proportion of cases with a flat audiogram and
an AA-genotype. However, as already stated above, sample
numbers in the Ghent subsample were small, and this obser-
vation could be due to chance. A statistical analysis stratifying
for audiogram shape but using higher sample numbers might
find an explanation for the aberrant picture observed in the
Ghent subsample.
Previously, other ARHI susceptibility genes, such as
KCNQ4, NAT2 and others, have been proposed (30–33).
Interestingly, KCNQ4 was one of the candidate genes in this
study. Despite the fact that the samples in the current study
were collected identically to the samples for the second popu-
lation used in the Van Eyken et al. (32) study, we failed to
replicate our previous findings. The highest rank a KCNQ4
SNP obtained within the analysis of all samples combined
was 71. NAT2, GSTM1, GSTT1 and APOE were not among
the candidate genes selected for the current study.
GRHL2 is a transcription factor that is widely expressed in a
variety of epithelial tissues (34). In the inner ear, GHRL2 is
Figure 1. Barcharts of the GRHL2 SNP rs10955255 genotypes for all subsample sets. Worse hearing subjects (cases) are indicated with a lighter shaded box,
while better hearing subjects (controls) are indicated with a darker shaded box. X-axis refers to the genotypes, while the Y-axis refers to the number of subjects.
AN, Antwerp; CF, Cardiff; CO, Copenhagen; GE, Ghent; NY, Nijmegen; OU, Oulu; PA, Padova; TA, Tampere and TU, Tu¨bingen.
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Table 7. GRHL2 fine mapping (statistical analysis of all samples combined)
SNP
number
SNP name Coordinate MAF Homogeneity P-value OR
18 rs10955255 102605581 0.411 0.2948 8.3831025 1.27
20 rs2127034 102611574 0.484 0.5885 0.000160 0.80
21 rs13263539 102613455 0.484 0.5854 0.000249 0.80
22 rs606338 102621097 0.192 0.3180 0.026085 1.19
23 rs1981361 102621953 0.412 0.0728 0.000529 0.81
25 rs17398001 102623393 0.163 0.6165 0.007620 0.80
27 rs3735709a 102624650 0.026b 0.3023 0.841249 0.97
52 rs17399841 102685908 0.052 0.4230 0.034905 1.34
53 rs632216 102686966 0.035b 0.9767 0.041068 0.71
55 rs548187 102696425 0.003b 0.5834 0.033314 0.32
63 rs7827945 102732501 0.255 0.1364 0.026129 0.86
Significant P-values have been indicated in bold.
Only significant SNPs are shown in addition to the non-synonymous SNP rs3735709 in exon 2. For an overview of all 67 SNPs, see Supplementary Material,
Table S2.
aThe NCBI information for rs3735709 is erroneous. According to NCBI the A-allele of the reference sequence is substituted for a T-allele, thereby changing lysine
into isoleucine at amino acid position 9. However, by sequencing exon 2 in 32 individuals we consistently found the A-allele to be substituted for a G-allele,
leading to an arginine at amino acid position 9.
bResults for SNPs with MAF ,0.05 may not be reliable. These SNPs were also omitted from Figure 2.
Figure 2. Genomic organization and LD within GRHL2. LD patterns were generated by Haploview. D0 is depicted. SNPs with MAF,0.05 were omitted from the
LD analysis. The 18 kb LD-block that was manually imposed in Haploview to determine the risk haplotype is indicated. In the upper part of the figure the
genomic organization of GRHL2 is depicted. Exons are indicated with black boxes, putative promoter regions as predicted by Eldorado (Genomatix) are indi-
cated with green boxes, and significantly associated SNPs are indicated with red lines. The most significantly associated SNP, rs10955255, is indicated with a red
asterisk.
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expressed in cells lining the cochlear duct, most prominent
during embryonic development and less during early postnatal
stages (35). GHRL2 belongs to a family of homologues of the
Drosophila gene grainyhead (34,36). In Drosophila, grainy-
head is critical for the regulation of several important develop-
mental processes and homozygous mutations in this gene are
embryonic lethal (34). The three mammalian homologues
(GRHL1 to 3) are expected to be of equal importance during
mammalian embryogenesis as all three genes are highly
expressed in the developing epidermis. Interestingly, they
display subtle differences in timing and level of expression,
indicating that the three genes may not be redundant (37).
A frameshift mutation in GHRL2 (1609–1610insC), leading
to a truncation in exon 14 if the mRNA would be translated
into protein, is responsible for DFNA28 autosomal dominant
hearing loss (35). So far, no additional mutations in GRHL2
have been described. The hearing loss in the family segregat-
ing c.1609–1610insC can be categorized as mild to moderate
across all frequencies in the initial stages, but progressing
towards severe hearing loss of the high frequencies in the
fifth decade. The age at onset is variable, with the youngest
patient diagnosed in his first decade. As such, DFNA28
hearing loss does not completely match the typical features
observed in ARHI, but some properties certainly correspond,
such as the progressive and sensorineural nature, and the
fact that the high frequencies are most affected later in life.
Although additional transcription factors have been implicated
in autosomal dominant types of hearing loss before [EYA4
(eyes absent, drosophila, homologue of, 4) – DFNA10 (38)
and POU4F3 (pou domain, class 4, transcription factor 3) –
DFNA15 (39)], it was rather unexpected that a transcription
factor with an important function during developmental
stages was identified as the gene responsible for childhood-
onset progressive hearing loss. However, this fact probably
implies that, besides functioning during embryonic develop-
ment, GRHL2 also functions in epithelial cell maintenance
throughout life (35). An impaired maintenance, albeit to a
lesser degree, is most probably also the underlying pathologi-
cal reason of GRHL2s involvement in a form of late-onset
hearing impairment such as ARHI. Being aware of more
recent clinical data, especially for DFNA15 (40), it is not unli-
kely to find that a transcription factor is involved in ARHI.
Moreover, another transcription factor has been implicated
recently in late-onset disease; TCF7L2 (transcription factor
7-like 2) was established as susceptibility gene for type 2 dia-
betes (41,42). Therefore, although transcription factors do not
pose obvious candidates for late-onset diseases, the involve-
ment of GRHL2 in ARHI is not exceptional at all.
As we excluded a non-synonymous SNP from exon 2 as
putative causative SNP, and as exon 2 is not actually part of
the 18 kb LD-block containing the most significant SNPs, it
is most likely that the causative variant(s) will reside in the
18 kb LD-block located in intron 1. Interestingly, this intronic
region contains a few evolutionary conserved regions, one of
which coincides with a predicted promoter region. GRHL2
has at least two isoforms (Uniprot, URL:http://www.ebi.
uniprot.org/entry/Q6ISB3). The complete protein (isoform 1)
consists of 625 amino acids. Isoform 2 is encoded by an
mRNA with an alternatively spliced exon 1 that is extended
with 60 nucleotides from intron 1, immediately downstream
of exon 1. A stop codon is present in this alternative 30 end
of exon 1 which may force the translation start of isoform 2
towards a methionine in exon 2. This would lead to an
isoform 2 that lacks the first 16 amino acids of isoform 1.
The first three exons of GRHL2 encode a transcriptional acti-
vation domain (34). Isoform 2 may therefore regulate tran-
scription differently compared to isoform 1. It is tempting to
speculate that isoform 2 might be driven both by a general
GRHL2 promoter upstream of exon 1 and by an alternative
promoter that is localized in intron 1. Alternatively, the
expression of yet another, so far unidentified isoform may
be driven by the alternative promoter in intron 1. A common
variant present in this alternative promoter may be responsible
for either increased or decreased expression levels in subjects
who are susceptible to ARHI. We did not succeed in amplify-
ing GRHL2 with RT–PCR on lymphocyte mRNA. Indeed, the
GNF SymAtlas (Genomics Institute of the Novartis Research
Foundation, URL:http://symatlas.gnf.org/SymAtlas/) indicates
that expression levels in lymphocytes are low. This implies
that testing for an association between GRHL2 expression
levels and ARHI cannot easily be achieved and no evidence
for our hypothesis can be provided in this way. To further
address the identification of the causative variants, the 18 kb
region of intron 1 can be resequenced in risk haplotype car-
riers and non-carriers, in order to document all common vari-
ation that is present in this region. Subsequent association
studies should provide several putative causative variants,
whose involvement in ARHI will be studied further by
means of relevant functional studies.
It is well established that transcription factors obtain func-
tional diversity through the presence of tissue-specific iso-
forms and through the formation of homo- and heteromeric
complexes (34,36). Alternative splicing can generate specific
isoforms and as such modulate DNA binding specificity or
affinity, produce activators and repressors from the same
gene and modulate dimerization (43). GRHL2 is known to
homodimerize and to form heterodimers with GRHL1 (34)
and GRHL3 (36). However, elucidation as to which GRHL2
isoforms and homo- and/or heterodimers are present in the
inner ear is necessary. The functional properties of GRHL2
Table 8. Determination of the risk haplotype in the associated 18 kb LD block
Haplotypea Frequency P-value
GCAATAGAG 0.505 3.031024b
ACGGAGGAA 0.099 0.3690
ACGGTGGAG 0.097 0.4903
ACGGTGGCG 0.089 0.0305
ACGGTAGAG 0.042 0.0882
GCGGAGGAA 0.030 0.9027
ACGGAGGCG 0.026 0.0122
GCGGTAGCG 0.021 0.3585
ATGGAGGAA 0.017 0.9812
GCGGTGGCG 0.011 0.9933
Significant P-values have been indicated in bold.
aHaplotypes were deduced for the following SNPs: rs10955255, rs812890,
rs2127034, rs13263539, rs606338, rs1981361, rs12114698, rs17398001 and
rs470801. Rs812890 and rs12114698 were omitted from Figure 2 because they
had a MAF of ,0.05.
bPermutated P-value is 0.0005 (10 000 permutations).
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within the inner ear will also critically depend on the presence
of its target genes. Human homologues of Drosophila
grainyhead target genes, like EN-1 (human engrailed homol-
ogue) have been identified, but it remains to be seen which
of these genes are regulated by GRHL2 as most of the
efforts have concentrated on the identification of target
genes for GRHL1 (34). So far no mouse model is available,
although a mouse lacking Grhl2 may be imminent (37).
However, for our purposes, i.e. the study of a maintenance
role for GRHL2 in cochlear epithelial cells, a conditional
knockout in which the gene can be switched off in adult
inner ear, would be a more relevant animal model.
In conclusion, our candidate gene approach revealed
GRHL2 as ARHI susceptibility gene, as highly significant
associations were observed for the complete sample set and
replication was found in two independent populations. Fine
mapping localized the region of interest in an 18 kb
LD-block within intron 1, but further experiments will be
necessary to identify the causative variant(s).
MATERIALS AND METHODS
Subjects
The subjects have previously been described (29,31). Briefly,
Caucasian volunteers, 53–67 years of age, from nine centers
in seven European countries, were collected via population
registries or via audiological consultations. If the subjects
were collected via hearing health services, the subjects’
spouses were also included. All subjects underwent an oto-
scopic investigation. Subjects with ear diseases potentially
affecting hearing thresholds were excluded from the study.
All subjects completed an extended questionnaire detailing
medical history and exposure to environmental factors. In
general, subjects with pathologies that could potentially influ-
ence their hearing thresholds were excluded according to an
extensive exclusion list (32). Air conduction thresholds were
measured at 0.125, 0.25, 0.5, 1, 2, 3, 4, 6 and 8 kHz, and
bone conduction at 0.5, 1, 2 and 4 kHz for all participating
volunteers. Audiological exclusion criteria were a conductive
gap of more than 15 dB averaged over 0.5, 1 and 2 kHz in
one or both ears or asymmetrical hearing impairment with a
difference in air conduction thresholds exceeding 20 dB in at
least two frequencies between 0.5, 1 and 2 kHz. Informed
consent was obtained from all volunteers. The study was
approved by the ethical committees of the respective recruit-
ing centers.
Z-score calculations and sample selection
Z-scores were calculated as described previously (32,44).
Briefly, frequency-specific thresholds were converted to sex
and age independent Z-scores based on the ISO 7029 standard
(45). These Z-scores represent the number of standard devi-
ations the actual hearing threshold differs from the median
at a given frequency. Subjects whose hearing is better than
the age and sex specific median at a certain frequency have
a negative Z-score. As a measure of high frequency hearing
impairment, the Z-scores at 2, 4 and 8 kHz were averaged
(Zhigh). This was done separately for both ears but only the
Z-score for the better hearing ear was used. After excluding
phenotypic outliers for Zhigh, we selected the 34% best and
34% worst hearing subjects within each center, for males
and females separately (Table 1 and Supplementary Material,
Fig. S1). Subsequently, the phenotype was dichotomized by
labeling the two distribution extremes as cases and controls.
Candidate gene and SNP selection
A list of candidate genes was generated based on the literature
and information available on several websites, including the
Hereditary Hearing Loss website (URL: http://webh01.ua.ac.
be/hhh/), the Jackson Laboratories Hereditary Hearing Impair-
ment in Mice website (URL: http://www.jax.org/hmr/) and the
Sanger Institute Deaf Mouse Mutants website (URL: http://
www.sanger.ac.uk/PostGenomics/mousemutants/deaf/). The
resulting list of 70 candidate genes mainly consisted of mono-
genic hearing loss genes identified in mice and men in addition
to several strong functional candidate genes (Table 2 and Sup-
plementary Material, Table S1). Subsequently, SNPs were
selected in all candidate genes. To achieve this, a list of all
SNPs that were present in the HAPMAP database (release
no. 16) (URL: http://www.hapmap.org/) in the genomic
region of the candidate gene and in a region 3000 bp upstream
of the gene (putatively containing regulatory elements) was
used as an input file for the MARKER computer program
(URL: http://www.gmap.net/marker). Based on the
HAPMAP data for these SNPs, MARKER was used to
select the tag SNPs. In addition, SNPs with proven or putative
biological relevance were selected from dbSNP (URL: http://
www.ncbi.nlm.nih.gov), the SNPeffect database (URL: http://
snpeffect.vib.be), the Genetic Association database (URL:
http://geneticassociationdb.nih.gov), and the ABI SNP data-
base (URL: http://appliedbiosystems.com). All selected SNPs
had a MAF of 0.05 or higher. The exact number of selected
SNPs per gene is shown in Supplementary Material,
Table S1. The designability of each selected SNP for the Illu-
mina GoldenGate genotyping assay was checked in consul-
tation with Illumina (San Diego, CA, USA). SNPs, which
were undesignable (score of 0) or which had a low designabi-
lity score (score of 0.5) were replaced by other, if possible,
equally informative SNPs, depending on the output of a
Tagger analysis (URL: www.broad.mit.edu/mpg/tagger). All
768 SNPs on the final SNP list had the maximum designability
score of 1.0. A classification of the selected SNPs is given in
Table 3.
SNP genotyping
Assay design and genotyping of all SNPs on all selected
samples were performed by Illumina (San Diego). For each
center, four samples were genotyped in duplicate. As a
control for Illumina’s genotyping accuracy, a selection of
SNPs was genotyped in our laboratory on a subset of
samples using either the AcycloPrime-Fluorescence Polariz-
ation (FP) SNP Detection System (PerkinElmer Life Sciences,
Boston, MA, USA) or the SNaPshotTM Detection Method
(Applied Biosystems, Foster City, CA, USA) according to
the manufacturer’s instructions and as described previously
(32). In case of discrepancies, dye terminator cycle sequencing
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was performed using ABI procedures and equipment
(Applied Biosystems). The sequencing result was considered
the gold standard.
GRHL2 fine mapping
For GRHL2 fine mapping purposes, we selected additional tag
SNPs in the genomic region of the gene and 3000 bp upstream,
according to the information that was present in HAPMAP
release no. 22. There was no cut-off for the MAF. The relevant
HAPMAP data were dumped into Haploview and tag SNPs
were selected using the default settings (r2 ¼ 0.8; aggressive
tagging) of Tagger. This resulted in a total of 44 additional
tag SNPs, excluding those SNPs that had previously been
genotyped by Illumina (n ¼ 26). In addition to the selected
tag SNPs, a non-synonymous SNP located in exon 2
(rs3735709) was added to the list, resulting in a total
number of 45 SNPs that were genotyped by Kbioscience
(Hoddesdon, UK).
Additional bioinformatical analysis
LD patterns of candidate genes were determined with the
default settings of Haploview 3.32 (URL: www.broad.mit.
edu/mpg/haploview/) using all available genotyping data.
Haploview 3.32 was also used to determine the risk haplotype
after manually imposing the LD block of interest. Prediction
of promoter and regulatory regions in GRHL2 was performed
with the Eldorado software package (Genomatix; URL: http://
www.genomatix.de/). Comparative analysis of human and
mouse GRHL2 genomic sequences was performed using
VISTA Tools (URL: http://genome.lbl.gov/vista/) (46,47).
Data polishing
The first stage in the data polishing process consisted of
removing all samples with 10% or more missing genotypes.
Subsequently, SNP assays with more than 4% missing geno-
types among all genotyped subjects were excluded. Gender
mis-specification was checked by matching the gender
deduced from sex-specific control loci with the gender that
was provided in the sample list. A subsequent step consisted
of Hardy–Weinberg equilibrium testing for every approved
SNP on all approved samples by x2-testing. Based on a signifi-
cance level of 0.001 all SNP assays were in Hardy–Weinberg
equilibrium. The final step of the polishing process consisted
of the detection and removal of genetic outliers, using
CHECKHET (48) and GRR (URL: http://bioinformatics.
well.ox.ac.uk/GRR) (49). As a homogeneous genetic back-
ground of each independent sample set enhances the power
of a genetic association study, CHECKHET can be used to
detect small numbers of subjects with a different genetic back-
ground when compared to the genetic background of the
majority of the tested samples. The presence of related indi-
viduals in association studies using unrelated samples could
lead to incorrect conclusions. GRR detects putative relatives
on the basis of the fact that related individuals share an
excess of alleles identical by state. In addition, GRR is also
capable of detecting sample duplications. The cut-off value
for exclusion was 1.75 on a scale of 2.0 identical by state.
Statistical analysis
Logistic regression was performed on the genotyping data of
samples from the nine centers as a whole and on the data
of samples from the nine centers separately. As the presence
of population stratification, i.e. the existence of (often unob-
served) subgroups within the study population that differ
both in allele frequencies and in baseline risk of disease,
may lead to spurious associations, the subject origin was
taken into account in the combined analysis. We assumed an
additive genetic effect on the logit scale so that genotypes
were coded as 0, 1 or 2 and that genotype was treated as a con-
tinuous covariate in the logistic regression model. To test for
homogeneity across the nine recruiting centers in the com-
bined analysis, we first fitted a full model containing main
effects for center (eight dummy variables) and genotype, and
interaction terms between center and genotype. Using a likeli-
hood ratio test, this model was compared with a reduced
model without the eight interaction terms. When this test
was non-significant, a homogeneous effect of the genotype
across all centers was assumed. The model was refitted and
the genotype effect was tested using a likelihood ratio test.
The main effects of center were retained in this model to
account for small artificial differences in ‘disease prevalence’
because of lost samples due to poor DNA quality or ‘no gen-
otype’ calls. We realize that additional hidden population
structure might be present within populations, but the impact
of this on the results of genetic association studies has been
demonstrated to be of minor importance within Europe (50).
ORs were calculated by exponentiating regression coefficients
obtained from the logistic regression model. The FDR was
calculated according to Storey and Tibshirani (51).
An allelic heterogeneity test was performed for the GRHL2
region in order to test how many association signals were
present (52). Briefly, we started with a logistic regression
model containing only the origin and the genotype of the
most significant SNP (rs10955255). Unlike the initial signifi-
cance test, a genotypic model (two degrees of freedom) was
fitted for this latter SNP, making no assumption about the
mode of inheritance. Subsequently, we added each of the
remaining significant SNPs separately to the model and
tested if the model fit significantly improved (likelihood
ratio test, 1 degree of freedom, additive model). In case the
added SNP gave no significant improvement in model fit,
we concluded that the added SNP represented the same associ-
ation signal as the most significant SNP, and that its signi-
ficance was merely due to LD with the most significant
SNP. If adding a SNP significantly improved the model fit,
we concluded that this particular SNP represented an indepen-
dent association signal.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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